You are here
CRT has an unusually broad portfolio of cancer-focused projects, a pipeline that rivals most pharmas', and we're ranked second for the number of oncology licenses completed.
CRT currently has more than 30 partnered agents in pre-clinical and clinical development, two drugs in phase III trials and four drugs already on the market and benefiting patients.View our pipeline
CRT has more than 200 oncology-focused projects under development and potentially available for licensing or collaboration. The projects range from discovery to clinical.Search our opportunities
We’ve been involved in the formation of more than 30 spin-outs – some of which have achieved significant exits through acquisition by leading pharmaceutical companies. Read more.